MyeloMATCH MSRP: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study
Status:
Not yet recruiting
Trial end date:
2032-05-12
Target enrollment:
Participant gender:
Summary
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a
screening tool and specific laboratory tests to help improve participants' ability to
register to clinical trials throughout the course of their myeloid cancer (acute myeloid
leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone
marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any
molecule in the body that can be measured. Doctors look at markers to learn what is happening
in the body. Knowing about certain markers can give doctors more information about what is
driving the cancer and how to treat it. Testing patients' bone marrow and blood will show
doctors if patients have markers that specific drugs can target. The marker testing in this
study will let doctors know if they can match patients with a treatment study (myeloMATCH
clinical trial) that tests treatment for the type of cancer they have.